Ostemax (Alendronate Sodium Trihydrate)

Alendronate sodium trihydrate binds to bone mineral at sites of active remodeling and is taken up by osteoclasts. It inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which impairs osteoclast function, reduces bone resorption, and ultimately leads to stronger, denser bone.

The dosage of Ostemax is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and calcium status. Patients should follow the prescriber’s instructions and take the medication exactly as directed on the prescription label.

Safety of Ostemax in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Ostemax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Ostemax belongs to the bisphosphonate class, which is widely used as a first‑line therapy for osteoporosis. Compared with other options such as selective estrogen receptor modulators or monoclonal antibodies, bisphosphonates like alendronate have a well‑established efficacy profile for reducing vertebral and non‑vertebral fractures, though individual patient factors guide the optimal choice.

Ostemax should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or other humid environments.

Ostemax is taken orally, usually as a single tablet taken with a full glass of plain water on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating or drinking anything other than water during that period to maximise absorption.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, and severe esophageal ulceration. Patients should promptly report persistent jaw pain, new thigh or groin pain, or difficulty swallowing, as early detection and management are essential for these rare but significant complications.

Ostemax is contraindicated in patients with known hypersensitivity to alendronate or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders, or individuals unable to remain upright for 30 minutes after dosing.